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Adenosine is a neuromodulator which is involved in a multitude of both physiological 
and pathological mechanisms in the body. Within the CNS, adenosine plays an 
important role in the regulation of motor processes and behaviour. Its biological effects 
are mediated through interaction with one of four G protein-coupled, membrane-bound 
receptor subtypes currently known as A1, A2A, A2B and A3. The adenosine A1  and A2A 
receptors predominate in the brain whereas the adenosine A2A receptors are mainly 
located in the striatum. In the striatum, the adenosine A2A receptors antagonistically 
interact with colocalized dopamine D2 receptors. A degeneration of the striatum with a 
progressive depletion of dopamine leads to the clinical situation of Parkinson´s 
Disease. This disease belongs to the most common neurodegenerative disorders in 
Germany. The motor impairment which comes along with this disease can be improved 
with adenosine A2A receptor antagonists. In addition to this antiparkinsonian effect, 
animal models of depression also indicate an antidepressant effect of these 
compounds. Depression is a psychiatric disease with a high prevalence within the 
population. In European countries, 5-10 % of the population is affected. The exact 
pathophysiological mechanisms that underlie human depression are not yet completely 
understood. Besides the involvement of serotonine and noradrenaline, dopamine also 
seems to play an important role. 
The goal of this project was to investigate the effect of three adenosine receptor 
antagonists of different subtypselectivity to the adenosine A2A receptors in the 
Haloperidol-induced catalepsy, an animal model for Parkinson´s disease, and in two 
animal models of depression, namely the Forced Swim Test and the Olfactory 
Bulbectomy. The substances used in this project were the unselective adenosine 
receptor antagonist Theophylline, the moderately selective elbion substance A and the 
highly selective KW-6002.   
In the Haloperidol-induced catalepsy, a possible correlation of the anticataleptic effect 
and the level of subtypselectivity of the investigated adenosine receptor antagonists 
was examined in addition to the time-effect curve. All three substances led to a clear 
reduction of the Haloperidol-induced catalepsy in the mouse and the rat. Differences in 
the level of effect and its duration were produced by pharmacokinetic parameters 
rather than the level of subtypselectivity.   
The anticataleptic effective compounds were then examined for an antidepressant 
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effect in the Forced Swim Test in mice. The examined dosages of all three adenosine 
receptor antagonists revealed an antidepressant effect by significantly reducing the 
immobility time. This antidepressant effect was further investigated in the Olfactory 
Bulbectomy in rats, a valid animal model of depression. The removal of the olfactory 
bulbs induces numerous neurochemical, neuroendocrine and neuroimmune changes 
and also changes in the rats' behaviour. So bulbectomized rats show hyperactivity in a 
new, aversive environment. Paralleling the clinical situation in humans, this behavioural 
feature is reversed only by chronic treatment with antidepressants and not after acute 
treatment like in the Forced Swim Test. The adenosine receptor antagonists were 
applied to the animals for fifteen days. The antidepressant effect of the adenosine 
receptor antagonists that could be observed in the Forced Swim Test could not be 
seen in the Olfactory Bulbectomy. Unlike Imipramine and Amitriptyline, the two 
reference compounds, the treatment with adenosine receptor antagonists did not 
attenuate the hyperactivity of the bulbectomized rats. Theophylline (30 mg/kg b.w. p.o. 
sid), elbion substance A (30 mg/kg b.w. p.o. bid) and KW-6002 (10 mg/kg p.o. sid) 
further increased the locomotor activity of the bulbectomized rats. A statistically 
significant effect however was only achieved after treatment with elbion substance A. In 
the sham-operated animals, treatment with Theophylline and KW-6002 also led to an 
increase in locomotor activity in the Open Field. Due to this stimulative effect of 
adenosine A2A receptor antagonists an antidepressant efficacy of the adenosine 
receptor antagonists in the Forced Swim Test should be evaluated cautiously. It is 
possible that the antidepressant effect in the Forced Swim Test reveals a false positive 
result. The Olfactory Bulbectomy is mainly used as an animal model for agitated 
depression. The likelihood is that it is not the adequate model for detecting an 
antidepressant efficacy of motor stimulating compounds. A false negative 
antidepressant effect of the investigated adenosine receptor antagonists in this model 
seems to be likely. Clinical studies in patients with different forms of depression should 
show whether adenosine A2A receptor antagonists are suitable for an antidepressant 
treatment especially of the inhibited depression.  
